In 2014, the Bill and Melinda Gates Foundation and the Wellcome Trust invested $40 million in Kymab. This was followed by Series B financing in 2015, in which Woodford Patient Capital Trust plc and Malin Corporation plc invested US$50 million. We secured $100 million in November 2016, with investment from ORI Fund and Hepalink as well as follow-on investments from existing shareholders.
In 2010, the Wellcome Trust Investment Division led an initial $30 million financing. This enabled us to develop the Kymouse™ platform and create value through the development of an in-house therapeutic antibody portfolio and build partnerships with other companies.
Our Series B financing totalled over $90 million with investment from Woodford Patient Capital Trust plc and Malin Corporation plc, and from the largest healthcare foundations in the world, the Bill & Melinda Gates Foundation and the Wellcome Trust, which hold combined funds of $68 billion.
We completed our Series C financing in November 2016, securing $100 million investment from ORF Fund and Hepalink, as well as follow-on investments from existing shareholders.
These investments enable our mission to advance our pipeline of first-in-class therapeutics and embark on vaccine R&D in areas of high unmet medical need.
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust’s breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests. The Wellcome Trust Investment Division invested in both the initial and Series B financing of Kymab.
Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. In developing countries, it focuses on improving people’s health and giving them the chance to lift themselves out of hunger and extreme poverty. In the United States, it seeks to ensure that all people—especially those with the fewest resources—have access to the opportunities they need to succeed in school and life. Based in Seattle, Washington, the foundation is led by CEO Dr Susan Desmond-Hellmann and Co-chair William H. Gates Sr, under the direction of Bill and Melinda Gates and Warren Buffett.
Malin is a newly established, Irish incorporated public limited company. Its purpose is to create shareholder value through the selective long-term application of capital and operational expertise to private, pre-IPO, pre-trade sale operating businesses in dynamic and fast growing segments of the life sciences industry. Malin will focus its efforts on acquiring majority or significant minority equity positions in companies with post investment valuations in the $10 million to $250 million range, and post-acquisition, on building optimal long term value.
Woodford Patient Capital Trust plc is the record-breaking investment trust that aims to achieve long-term capital growth through investing in a portfolio consisting predominantly of early-stage and early-growth companies. The trust is managed by Woodford Investment Management (Woodford), the fast-growing asset management company built on a founding philosophy of transparency and simplicity.
ORI Healthcare Fund (ORI Fund)
ORI Fund is a US$200 million venture capital fund focused on investing in innovative companies with disruptive technologies in the healthcare industry globally. The fund is founded by Ms. Simone (Hong Fang) Song, former investment banker and head of China Healthcare at Goldman Sachs. The team consists mostly of former Goldman Sachs bankers and healthcare scientists.
Shenzhen Hepalink Pharmaceutical Co. Ltd
Hepalink distributes its products, including Heparin Sodium API, in the global market to international pharmaceutical companies, such as Sanofi-Aventis, Fresenius-Kabi, and Novartis. Hepalink was established in 1998 and went public and was listed on the Shenzhen Stock Exchange on May 6, 2010 (stock code 002399). Hepalink’s headquarters are located in the Shenzhen High-Tech Park. Hepalink has established a comprehensive quality management system in line with China GMP standards and the US and European cGMP standards and regulations. Hepalink manufacturing facilities are approved by the US FDA and EU regulatory authorities, and it is also one of the primary participants in the revision of the USP pharmacopeia standards.